From proteomics to personalized medicine: the road ahead

Nice, Edouard C.

doi:10.1586/14789450.2016.1158107

Cited by 27 publications

(7 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides, some experiments were purely designed for biomarker discovery purpose whereby the identified secreted proteins from cell lines were subsequently validated in the patients’ samples. Such studies had identified collapsin response mediator protein‐2 (CRMP‐2) and melanotransferrin (TRFM) from the CRC cell line secretome analyses followed by confirmation on their elevated levels in the tumor and plasma samples of CRC patients. However, it is important to note that the CRC cells are never alone by nature.…”

Section: The Secretome Studies Of Colorectal Cancermentioning

confidence: 99%

“…In addition, the protein signatures that are identified from the microbes along with other secreted proteins from the host may be exploited not only as novel biomarkers in the form of completely non‐invasive CRC screening panel, but also realizing the potential of microbiome in precision medicine in the coming of years. The development of Integrative Personal Omics Profile (iPOP), that integrates multiple omics technologies; genomic, transcriptomic, proteomic, metabolomic and autoantibody profiles, as well as the Human Personalized Omics Profiling (hPOP) are the striking initiatives towards personalized medicine . In our opinion, the observational secretomic data of gut microbiome from a disturbed tumor environment is indispensable and will pave the way for more advanced hypothesis‐driven studies in model organism, before the ultimate translation to the patient.…”

Section: Future Outlookmentioning

confidence: 99%

See 1 more Smart Citation

Analyzing the Secretome of Gut Microbiota as the Next Strategy For Early Detection of Colorectal Cancer

et al. 2019

View full text Add to dashboard Cite

Dysbiosis of gut microbiome can contribute to inflammation, and subsequently initiation and progression of colorectal cancer (CRC). Throughout these stages, various proteins and metabolites are secreted to the external environment by microorganisms or the hosts themselves. Studying these proteins may help enhance our understanding of the host–microorganism relationship or they may even serve as useful biomarkers for CRC. However, secretomic studies of gut microbiome of CRC patients, until now, are scarcely performed. In this review article, the focus is on the roles of gut microbiome in CRC, the current findings on CRC secretome are highlighted, and the emerging challenges and strategies to drive forward this area of research are addressed.

show abstract

Section: The Secretome Studies Of Colorectal Cancermentioning

confidence: 99%

Section: Future Outlookmentioning

confidence: 99%

Analyzing the Secretome of Gut Microbiota as the Next Strategy For Early Detection of Colorectal Cancer

et al. 2019

View full text Add to dashboard Cite

show abstract

“…WTS also cannot capture posttranslational processing and modifications, which have significant functional impacts. Correlation of WGS with proteomics technologies may enable further advances in personalized cancer care, but various technological, scientific, and logistic obstacles must first be overcome to catalyze clinical translation (Duarte and Spencer 2016;Kwon et al 2016;Nice 2016).…”

Section: Complementarity With the Transcriptomementioning

confidence: 99%

Whole-Genome Sequencing in Cancer

Zhao

Jones

2018

Cold Spring Harb Perspect Med

View full text Add to dashboard Cite

“…biomarker‐strategy design, enrichment‐design, biomarker‐stratified, ii) Bayesian designs (Bayesian adaptive randomized design), or iii) hybrid Bayesian‐frequentist approaches . These biomarker‐guided clinical trials open a new perspective for adaptation of the therapeutic intervention based on the specific molecular profiles of individual patients, rather than the conventional therapy decision means, where therapy is mostly guided by the symptoms or the results of the pathological examination …”

Section: Concept Of Personalized Medicinementioning

confidence: 99%

Clinical Proteomics for Precision Medicine: The Bladder Cancer Case

Latosinska

Frantzi

Vlahou

et al. 2017

Proteomics Clinical Apps

View full text Add to dashboard Cite

Precision medicine can improve patient management by guiding therapeutic decision based on molecular characteristics. The concept has been extensively addressed through the application of -omics-based approaches. Proteomics attract high interest, as proteins reflect a "real-time" dynamic molecular phenotype. Focusing on proteomics applications for personalized medicine, a literature search was conducted to cover: a) disease prevention, b) monitoring/ prediction of treatment response, c) stratification to guide intervention, and d) identification of drug targets. The review indicates the potential of proteomics for personalized medicine by also highlighting multiple challenges to be addressed prior to actual implementation. In oncology, particularly bladder cancer, application of precision medicine appears especially promising. The high heterogeneity and recurrence rates together with the limited treatment options, suggest that earlier and more efficient intervention, continuous monitoring, and the development of alternative therapies could be accomplished by applying proteomics-guided personalized approaches. This notion is backed by studies presenting biomarkers that are of value in patient stratification and prognosis, and by recent studies demonstrating the identification of promising therapeutic targets. Herein, we aim to present an approach whereby combining the knowledge on biomarkers and therapeutic targets in bladder cancer could serve as basis towards proteomics-guided personalized patient management.

show abstract

From proteomics to personalized medicine: the road ahead

Cited by 27 publications

References 17 publications

Analyzing the Secretome of Gut Microbiota as the Next Strategy For Early Detection of Colorectal Cancer

Analyzing the Secretome of Gut Microbiota as the Next Strategy For Early Detection of Colorectal Cancer

Whole-Genome Sequencing in Cancer

Clinical Proteomics for Precision Medicine: The Bladder Cancer Case

Contact Info

Product

Resources

About